Article
Multidisciplinary Sciences
Abdelnour H. Alhourani, Tia R. Tidwell, Ansooya A. Bokil, Gro Rosland, Karl Johan Tronstad, Kjetil Soreide, Hanne R. Hagland
Summary: This study investigated the impact of glucose concentration on cancer cells' response to metformin, highlighting the diverse reactions based on different growth rates and metabolic phenotypes under varying glucose conditions. The results demonstrate the importance of growth conditions in determining the effectiveness of metabolic drugs like metformin in cancer therapy.
SCIENTIFIC REPORTS
(2021)
Article
Multidisciplinary Sciences
Qinghua Luo, Ping Zhou, Shuangqing Chang, Zhifang Huang, Xuebo Zeng
Summary: This study investigated the role of butyrate metabolism in colorectal cancer (CRC) and developed a prognostic model based on differentially expressed butyrate metabolism-related genes. The model can predict the survival rate of CRC patients and identify potential markers or targets for treatment. It also has the potential to guide personalized cancer chemotherapy and immunotherapy.
SCIENTIFIC REPORTS
(2023)
Letter
Gastroenterology & Hepatology
Jan Dimberg, Levar Shamoun, Kalle Landerholm, Dick Wagsaeter
Summary: The association between type 2 diabetes mellitus (DM) and colorectal cancer (CRC) has been investigated, with reports suggesting an increased risk of CRC in DM patients. Metformin, with its anti-inflammatory effects, may protect against the development of CRC in DM patients and improve prognosis. However, in this cohort study, there were no associations between the presence of DM or metformin and cancer specific survival, plasma levels of inflammatory factors or irisin. A specific single nucleotide polymorphism in the insulin-like growth factor binding protein 7 gene was associated with DM in CRC patients.
WORLD JOURNAL OF GASTROENTEROLOGY
(2022)
Review
Food Science & Technology
Samuel Amintas, Charles Dupin, Julian Boutin, Pauline Beaumont, Francois Moreau-Gaudry, Aurelie Bedel, Stephanie Krisa, Veronique Vendrely, Sandrine Dabernat
Summary: Colorectal cancer (CRC) is a common cancer worldwide, linked to occidental diets. A diet rich in fruits and vegetables can help prevent CRC, and BFCs have potential in CRC prevention and treatment. However, the clinical applicability of BFCs still faces challenges.
CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION
(2023)
Article
Oncology
Mehmet Akce, Batoul Farran, Jeffrey M. Switchenko, Manali Rupji, Sandra Kang, Lana Khalil, Amanda Ruggieri-Joyce, Brian Olson, Walid L. Shaib, Christina Wu, Olatunji B. Alese, Maria Diab, Gregory B. Lesinski, Bassel F. El-Rayes
Summary: The combination of nivolumab and metformin did not demonstrate efficacy in patients with MSS CRC. While metformin alone did not show significant immune modulation effects, the dual treatment showed trends in increasing tumor-infiltrating leukocytes and decreasing naive CD8+T cells in patient tissues.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Chemistry, Multidisciplinary
Li Song, Yu Hao, Chunjie Wang, Yikai Han, Yujie Zhu, Liangzhu Feng, Liyan Miao, Zhuang Liu
Summary: A liposomal nanomedicine that modulates the tumor microenvironment has been developed to enhance cancer immunotherapy. By encapsulating metformin and an oxaliplatin prodrug in liposomes, this nanomedicine reduces tumor hypoxia and induces immunogenic cell death, effectively suppressing tumor growth and reversing immunosuppression.
JOURNAL OF CONTROLLED RELEASE
(2022)
Article
Biology
Gaston Amable, E. duardo Martinez-Leon, Maria E. Picco, Osvaldo Rey
Summary: Metformin, a widely prescribed antidiabetic drug, has a protective effect on different cancers including colorectal cancer. Recent studies have shown that metformin at concentrations compatible with those detected in human intestines inhibits key molecules and signaling pathways associated with colorectal cancer development.
Review
Gastroenterology & Hepatology
Georgina R. Jones, Mark P. Molloy
Summary: Metformin, widely used in treating T2DM, has shown potential in reducing CRC risk, but the molecular mechanisms behind its gastrointestinal anti-cancer properties are complex and not well understood. Interaction between metformin, gut microbiota, and colonic epithelial mucosa may play a role in its protection against CRC.
DIGESTIVE DISEASES AND SCIENCES
(2021)
Review
Oncology
Angelika Buczynska, Iwona Sidorkiewicz, Adam Jacek Kretowski, Monika Zbucka-Kretowska, Agnieszka Adamska
Summary: Metformin treatment has pleiotropic actions, such as inhibiting inflammatory processes, enhancing antioxidant capacity, and improving glycemic and lipid metabolism, making it an attractive drug candidate for human trials. Promising results of metformin in various clinical trials are also summarized in this review.
Article
Oncology
Xiaowen Huang, Tiantian Sun, Jilin Wang, Xialu Hong, Huimin Chen, Tingting Yan, Chengbei Zhou, Danfeng Sun, Chen Yang, TaChung Yu, Wenyu Su, Wan Du, Hua Xiong
Summary: Using single cell RNA sequencing, this study shows that metformin remodels the immune landscape of colorectal cancer by increasing the proportion and function of CD8+ T cells and reprogramming tryptophan metabolism. This highlights metformin as a potential immunotherapeutic strategy for treating colorectal cancer.
Review
Nutrition & Dietetics
Stephanie Marie Cruz-Pierard, Teresa Nestares, Francisco J. Amaro-Gahete
Summary: Vitamin D supplementation has a protective effect in the prevention and treatment of CRC, while calcium intake shows contradictory effects and further studies are needed to understand its relevance in patients with CRC.
Article
Multidisciplinary Sciences
L. E. Anselmino, M. Baglioni, F. Malizia, N. Cesatti Laluce, C. Borini Etichetti, V. L. Martinez Marignac, V Rozados, O. G. Scharovsky, J. Girardini, M. J. Rico, M. Menacho Marquez
Summary: Drug repositioning accelerates drug development process, finding effective drugs with reduced side effects and lower costs. Combining metformin and propranolol shows potential as adjuvant therapy for both CRC and TNBC, as well as effective alternative for chemo-resistant CRC.
SCIENTIFIC REPORTS
(2021)
Review
Oncology
Jiazhou Yu, Qi Feng, Jean H. Kim, Yimin Zhu
Summary: This study found that adherence to a healthy lifestyle is associated with a reduced risk of colorectal cancer. Each additional healthy lifestyle factor is associated with a decreased risk of colorectal cancer. These findings suggest that promoting a healthy lifestyle could help reduce the burden of colorectal cancer.
FRONTIERS IN ONCOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Miran Rada, Lucyna Krzywon, Stephanie Petrillo, Anthoula Lazaris, Peter Metrakos
Summary: This retrospective cohort study examined the role of metformin in colorectal cancer liver metastases (CRCLM). Among 108 patients, 20 patients used metformin and showed significantly lower incidence of vessel co-opting RHGP tumors, recurrence rate, and extrahepatic metastases. Metformin users also had significantly higher survival outcome. These findings suggest that metformin administration may be associated with better prognosis of CRCLM.
Review
Oncology
Irene Yu, Rongrong Wu, Yoshihisa Tokumaru, Krista P. Terracina, Kazuaki Takabe
Summary: This manuscript provides a comprehensive review of the gut microbiome's impact on colorectal cancer, exploring microbial mechanisms, treatment advancements, potential options for diagnosis and prevention, and future research directions.
